Business
Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies for genetically defined cancers.
Black Diamond swung to profit and positive cash flow on Servier revenue while staying a clinical-stage oncology story.
The read at a glance✓ Audited against SEC data
- Business mix — Clinical-stage oncology MasterKey therapiesNote
- Revenue — $70.0M Servier revenue rowOK
- Profitability — Net income swung to $22.4MOK
- Cash — Free cash flow swung to $29.6MOK
- Equity — Equity rose 34.7%OK
- Insiders — 0 purchases / 0 salesNote
- Accounting — No current forensic screen in bundleNote
Where the revenue comes from
Fiscal 2025, as Black Diamond Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Reportable$70.0M
Leadership changes
From Black Diamond Therapeutics, Inc.'s own filings, the day they're filed.
- Erika Jones · principal financial officer · appointmenteff. 2024-10-07
- Fang Ni · departureeff. 2024-10-07
- Alexander Mayweg · Directors · departureeff. 2024-04-10
Latest filings
- 10-Q · Quarterly report2026-08-05
- 8-K · Company announcement2026-08-05
- 8-K · Company announcement2026-06-29
- 8-K · Company announcement2026-05-21
- 10-Q · Quarterly report2026-05-07
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Black Diamond Therapeutics, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.